NIH Award from the National Cancer Institute
Early Therapeutics Development with Phase II Emphasis
This was awarded under Dr. Walter Stadler's (MD, Professor of Medicine, Director, Genitourinary Program; Chair, Cancer Research Center's Clinical Trials Review Committee; Associate Dean for Clinical Research) Phase II contract
- Principal Investigators:
Hedy Lee Kindler, MD, Associate Professor, Department of Medicine; Medical Director, Gastrointestinal Oncology; Director, Mesothelioma Program; and
Ravi Salgia, MD, PhD, Professor, Department of Medicine; Director, Thoracic Oncology Research Program - Start Date: September 30, 2009
- Total Award Amount: $650,000
Public Health Relevance
Pancreatic cancer has the worst survival of any solid tumor: in 2008, there were an estimated 37,680 new cases and 34,290 deaths from this disease in the United States. The 5-year overall survival is consistently below 5%. As treatment options are limited, novel, truly effective therapeutics are desperately needed. Novel agents are clearly needed for this disease.
Project Description
This is a clinic trial that compares the median progression-free survival of advanced pancreatic cancer patients treated with the combination of gemcitabine plus GDC-0449 versus gemcitabine plus placebo.
This award is funded under the American Recovery and Reinvestment Act of 2009, NIH Award number: HHSN2610062201C
Walter Stadler, MD,
Professor of Medicine, Director, Genitourinary Program; Chair, Cancer Research Center's Clinical Trials Review Committee; Associate Dean for Clinical Research
Hedy Lee Kindler, MD,
Associate Professor, Department of Medicine; Medical Director, Gastrointestinal Oncology; Director, Mesothelioma Program
Ravi Salgia, MD, PhD,
Professor, Department of Medicine; Director, Thoracic Oncology Research Program